Thor Medical to supply alpha isotopes to UK drug discovery center

The US Food and Drug Administration (FDA) has accepted Uppsala-based Orexo’s resubmitted New Drug Application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose. A decision is expected by March 29, 2027.

Following promising Phase IIa results in heart attack patients, the Danish biotech company ResoTher Pharma plans to list on Spotlight Stock Market in Sweden in December 2026. The listing will take place through a reverse takeover of Hunter Capital RTO 1, valuing the combined company at around SEK 333 million.

SynAct Pharma has signed its first commercial partnership for its drug candidate resomelagon. Under the agreement, the Swedish company and the Brazilian pharmaceutical company Hipolabor will co-develop and commercialize the drug for the treatment of dengue in Brazil, one of the world’s largest dengue markets.

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

The partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care.

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval of Eli Lilly's Foundayo (orforglipron), a once-daily GLP-1 tablet for weight management and type 2 diabetes in adults. If approved, it will compete with Novo's Wegovy pill in Europe.

Danish Ascendis Pharma has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP), recommending EU approval of once-weekly TransCon CNP (navepegritide) for children with achondroplasia.